ArticleDrug design, development and therapy2025
Development of an Early-Warning Model for Predicting the Capecitabine-Induced Diarrhea.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diarrhea is primary adverse effect of capecitabine (Cap) causing treatment discontinuation. The aim of this study was to construct an early-warning model for predicting the Cap-induced diarrhea. Methods: A Cap-induced diarrhea model in mice was constructed in 36 mice, and the exposure levels of Cap and its five metabolites were quantified in plasma and colon and correlated their exposure levels to the diarrhea. The concentrations of metabolic enzymes and drug transporters were quantified in the colon of 62 colorectal cancer (CRC) patients, and an early-warning model was constructed using binary logistic regression. Results: Totally, 15 out of 36 mice were identified as diarrhea mice, and the exposure levels of Cap and metabolites did not show any differences between diarrhea and non-diarrhea mice in plasma, but in colon, the Cap and metabolites, except for dihydrofluorouracil and 5-fluoro-2'-deoxyuridine, presented significantly higher exposure levels in diarrhea mice. Furthermore, the expression levels of metabolic enzymes and drug transporters in the colon differed distinctly between diarrhea and non-diarrhea CRC patients. Finally, a binary logistic model based on cytidine deaminase (CDA) and solute carrier family 22 member 7 (SLC22A7) was constructed for early-warning of diarrhea induced by Cap: Y = 0.028 × CDA (pg/mL) - 0.518 × SLC22A7 (pg/mL) + 1.526, with the area under curve of 0.907 (specificity 100.0%, sensitivity 71.4%) for diarrhea CRC patients. Conclusion: This study constructed and validated, for the first time, an early-warning model of diarrhea caused by Cap based on metabolic enzymes and drug transporters in normal colon tissue, which may provide a new basis for accurate medication for CRC treatment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.